Anti-Mouse TER-119 (Erythroid Cells) – Recombinant in vivo Functional Grade

Fetal liver cells from a C57BL/6 mouse

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

TER-119 activity is directed against mouse Ter-119.

TER-119 is highly specific for erythroid cells, from early proerythroblasts to mature erythrocytes. TER-119 antigen is expressed on normal erythroid cells, but not erythroleukemia cells, even when induced with dimethylsulfoxide. TER-119 is not thought to interact with pluripotent hematopoietic stem cells in adult bone marrow.

TER-119 recognizes a 52 kDa cell surface protein that strongly associates with glycophorin A on the erythrocyte membrane ¹ . The antigen is not present on a number of tested cell lines, including T cell, B cell, macrophage, mast cell, fibroblast, epithelial, and murine erythroleukemia cultured lines.

TER-119 is a mouse erythroid lineage-specific rat monoclonal antibody that reacts with 100% of mature erythrocytes and 80-90% of day 14 fetal liver cells, after which the percentage of TER-119⁺ fetal cells declines to 40-50% ². Additionally, TER-119 stains 20-25% of adult mouse bone marrow cells and 2-3% of spleen cells, but not thymocytes or lymph node cells.

TER-119 was produced in Wister rats immunized with BALB/c fetal liver cells ¹ . Spleen cells were fused with X63.Ag8.653 myeloma cells to produce a hybridoma clone reactive against fetal liver cells. TER-119 recognizes a 7,9 di-O-acetyl sialic acid glyco-epitope ³ . Additionally, the epitope is sensitive to hemagglutinin esterase derived from bovine coronavirus (Mebus strain) but not influenza C.

1 Kina T, Ikuta K, Takayama E, et al. Br J Haematol. 109(2):280-287. 2000.
2 Ikuta K, Kina T, MacNeil I, et al. Cell. 62(5):863-874. 1990.
3 Mahajan VS, Alsufyani F, Mattoo H, et al. Glycobiology. 29(3):222-228. 2019.
4 Otani T, Nakamura S, Inoue T, et al. Exp Hematol. 32(7):607-613. 2004.
5 Brendt P, Rehfeld I, Kamphausen A, et al. Anaesthesia. 67(5):493-500. 2012.
6 Kimball A, Schaller M, Joshi A, et al. Arterioscler Thromb Vasc Biol. 38(5):1102-1114. 2018.
7 Juban G, Sakakini N, Chagraoui H, et al. Haematologica. 106(4):1106-1119. 2021.
8 Perik-Zavodskaia O, Perik-Zavodskii R, Nazarov K, et al. Int J Mol Sci. 24(21):15752. 2023.
9 Mqadmi A, Abramowitz S, Zheng X, et al. Immunohematology. 22(1):11-4. 2006.
10 Kumon K, Afify SM, Hassan G, et al. Sci Rep. 11(1):23977. 2021.